Zielen, Stefan
Duecker, Ruth Pia
Woelke, Sandra
Donath, Helena
Bakhtiar, Sharhzad
Buecker, Aileen
Kreyenberg, Hermann
Huenecke, Sabine
Bader, Peter
Mahlaoui, Nizar
Ehl, Stephan
El-Helou, Sabine M.
Pietrucha, Barbara
Plebani, Alessandro
van der Flier, Michiel
van Aerde, Koen
Kilic, Sara S.
Reda, Shereen M.
Kostyuchenko, Larysa
McDermott, Elizabeth
Galal, Nermeen
Pignata, Claudio
Pérez, Juan Luis Santos
Laws, Hans-Juergen
Niehues, Tim
Kutukculer, Necil
Seidel, Markus G.
Marques, Laura
Ciznar, Peter
Edgar, John David M.
Soler-Palacín, Pere
von Bernuth, Horst
Krueger, Renate
Meyts, Isabelle
Baumann, Ulrich
Kanariou, Maria
Grimbacher, Bodo
Hauck, Fabian
Graf, Dagmar
Granado, Luis Ignacio Gonzalez
Prader, Seraina
Reisli, Ismail
Slatter, Mary
Rodríguez-Gallego, Carlos
Arkwright, Peter D.
Bethune, Claire
Deripapa, Elena
Sharapova, Svetlana O.
Lehmberg, Kai
Davies, E. Graham
Schuetz, Catharina
Kindle, Gerhard
Schubert, Ralf
Funding for this research was provided by:
Johann Wolfgang Goethe-Universität, Frankfurt am Main
Article History
Received: 28 January 2021
Accepted: 25 June 2021
First Online: 3 September 2021
Declarations
:
: The study was conducted following the ethical principles of the Declaration of Helsinki, regulatory requirements, and the code of Good Clinical Practice. The study was approved by the responsible ethics committees in Frankfurt (Date May 22, 2012/No. 121/12, Date Nov 21, 2016, No. 504/15).
: Informed consent was obtained from all individual participants included in the study.
: Written informed consent for publication of their clinical details and was obtained from the patient/parent/guardian/relative of the patient. A copy of the consent form is available for review by the Editor of this journal.
: The authors have the following conflicts to declare:Dr. Zielen reports honoraria from CSL-Behring, AstraZeneca; Sanofi-Aventis GmbH; Boehringer Ingelheim; Stallergenes Greer; Allergy Therapeutics, bene-Arzneimittel GmbH; Vifor Pharma GmbH; Novartis AG; GlaxoSmithKline GmbH; ALK-Abelló Arzneimittel GmbH; Lofarma GmbH, IMS Health GmbH & Co; and Biotest Pharma GmbH, outside the submitted work.Dr. Ehl reports grants from UCB, during the conduct of the study.Dr. Sabine M. El-Helou was funded by the Federal Ministry of Education and Research (BMBF), by the European Society for Immunodeficiencies (ESID), by the Care-for-Rare Foundation, by PROimmun e.V., and by a restricted grant from LFB, CSL Behring, and Grifols. For GAIN and RESIST, she was funded by the BMBF.Dr. Kindle reports grants from ESID (European Society for Immunodeficiencies) and grants from BMBF (German Federal Ministry of Education and Research), during the conduct of the study.Dr. van Aerde reports grants from Baxter, during the conduct of the study.Dr. Laws reports personal fees from Shire; Roche; Novonordisk; Pfizer; Csl Behring, outside the submitted work.Dr. Niehues reports honoraria from uptodate.com; travelling costs from PENTA and JIR cohorts (Padua, Italy; Lausanne Switzerland), up to 2017 from PPTA (plasma protein therapeutics association).Dr. Seidel reports personal fees from Shire [Hypogammaglobulinemia (Subcutaneous IgG, hyaluronic acid, immune globulin (human))], outside the submitted work.Dr. Meyts reports grants from CSL Behring, outside the submitted work. IM is a senior clinical investigator at FWO Vlaanderen (supported by CSL Behring Chair of Primary Immunodeficiencies, by a KU Leuven C1 Grant C16/18/007, by a VIB GC PID Grant, by a FWO Grants G0C8517N; and G0E8420N and by the Jeffrey Modell Foundation. IM is a recipient of a ERC-StG MORE2ADA2. This work is supported by ERN-RITA.Dr. Grimbacher reports grants from DZIF, DFG, BMBF, Fritz Thyssen Stiftung, Shire/Baxalta, Merck, BMS, Novartis, CSL Behring, personal fees from Janssen Cilag, Novartis, during the conduct of the study, outside the submitted work.Dr. Schubert reports grants from A-T Children’s Project, DFG, SPARKS–Action for A-T, Starke Lunge Foundation, personal fees from Biotest Pharma GmbH and Vifor Pharma Deutschland GmbH, outside the submitted work.The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.